|
December 10, 2009
Azaya Therapeutics Receives FDA Authorization to Start
Phase I Cancer Trial
November 11-13, 2009
Texas Life Science Conference 2009
The Brown Foundation Institute of Molecular Medicine
Houston, Texas
November 2-4, 2009
BIO-Europe 2009
Messe Wien Exhibition & Congress Center
Vienna, Austria
October 12-16, 2009
BioProcess International Conference and Exhibition
Raleigh Convention Center
Raleigh-Durham, North Carolina
October 5, 2009
Depomed, Inc. Announces Positive Top-Line Results from
Phase 3 Clinical Trial of DM-1796 in Postherpetic
Neuralgia
Menlo Park, Calif
September 22, 2009
Selexis and Neogenix Oncology enter into research
services agreement
Geneva, Switzerland, and Great Neck, New York
September 18, 2009
Wyeth and Ambrx Form Multi-target Alliance to Leverage
Recent Ambrx Biologics Platform Advances
Collegeville, PA and San Diego, CA
September 17, 2009
to-BBB technology will be used by MedImmune to evaluate
brain drug delivery mechanism
Leiden, The Netherlands
August 31, 2009
Selexis and NKT Therapeutics enter into research
services agreement
Geneva, Switzerland
August 10, 2009
Depomed Reports Encouraging Results of its Phase I Trial
for DM-1992 Program in Parkinson's Disease
Menlo Park, Calif
August 6, 2009
to-BBB climbs up the international CNS drug delivery
ranking
Leiden, The Netherlands
May 19, 2009
Personalized Medicine Can Increase Revenues
By Cammie Edwards, Ph.D., DNA Bridges, Inc.
Featured in Bio Show Daily, Tuesday, May 19, 2009.
Page 33.
May 19, 2009
Cell Therapy is Alive and Well
By Cori Gorman, Ph.D., MBA, DNA Bridges, Inc.
Featured in Bio Show Daily, Tuesday, May 19, 2009.
Page 22
May 12, 2009
U.S. Army funds TNO, and to-BBB to investigate
protecting soldier’s brains from nerve agents
May 8, 2009
Annual Sigma Xi Meeting
Lecture: The Thrill of Victory the Agony of Defeat, the
Trials of Developing a New Class of Therapeutics: From
Gene to Cell Therapy, A Case Study
May 5, 2009
Viroblock SA Reports a 99% Boost of Efficacy of
Facemasks against H5N1
April 14, 2009
Promising Test for Dendreon's Prostate Cancer Drug
April 11, 2009
FDA Approves Treatment of Head Lice - Target Health Was
THE CRO
April 7, 2009
Dr. Cori Gorman Completes ISS Certification in Corporate
Directors Enterprise 2009 Program
April 7, 2009
Editorial: Enabling High Throughput Drug Development
April 2, 2009
Editorial: Personalized Medicine Can Increase Revenues
March 31, 2009
Selexis launches Biosimilar Cell Line Development
Program
March 31, 2009
Positive Results of Preclinical Studies in Antiviral
Nasal Spray
March 24, 2009
Editorial: Cell Therapy Market
Cori Gorman, PhD, MBA
|
|
Highlights
DNA Bridges Articles
Calendar of Events
Archives
2010 | 2009
| 2008 |
2007 |
2006 |
2005 |
2004
2003 |
2002 |
2001 |
2000
|
